Cellectis (NASDAQ:CLLS – Get Free Report) is scheduled to announce its earnings results after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Cellectis (NASDAQ:CLLS – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.05. The business had revenue of $9.50 million for the quarter, compared to analyst estimates of $6.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. On average, analysts expect Cellectis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Cellectis Trading Up 1.1 %
Shares of CLLS stock opened at $1.80 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The company has a market cap of $100.05 million, a price-to-earnings ratio of -1.30 and a beta of 3.09. The stock has a 50 day simple moving average of $2.11 and a 200-day simple moving average of $2.29. Cellectis has a 1-year low of $1.77 and a 1-year high of $3.77.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on CLLS
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Featured Articles
- Five stocks we like better than Cellectis
- Compound Interest and Why It Matters When Investing
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- How to Buy Cheap Stocks Step by Step
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- What is Insider Trading? What You Can Learn from Insider Trading
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
